Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SebDuo is a compounded topical combination of the imidazole antifungal ketoconazole (8%) and the mid-potent corticosteroid triamcinolone acetonide (0.4%). Formulated as a concentrate, it is designed to be mixed with a patient's regular shampoo for the treatment of seborrheic dermatitis of the scalp. Ketoconazole acts by inhibiting fungal lanosterol 14-alpha-demethylase, thereby reducing the population of *Malassezia* yeast on the scalp, which is a key driver of seborrheic dermatitis. Triamcinolone acetonide acts as a glucocorticoid receptor agonist to provide rapid anti-inflammatory and antipruritic effects, relieving itching and redness. Developed by MedCara, SebDuo is compounded and distributed under prescription by licensed pharmacies such as NuCara Pharmacy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ketoconazole + triamcinolone acetonide.